Eli Lilly and Company has announced a major investment of over USD 1 billion in India over the next several years to enhance contract manufacturing capabilities and improve global access to innovative medicines. This move aligns with India’s Make in India agenda and demonstrates Lilly’s confidence in the country as a key hub for life sciences and healthcare manufacturing.
New Manufacturing & Quality Hub in Hyderabad
As part of this investment, Lilly will establish a Manufacturing & Quality hub in Hyderabad, offering advanced technical capabilities and oversight for its contract manufacturing network across India. This new facility will support the company’s growing portfolio of medicines for conditions such as diabetes, obesity, Alzheimer’s, cancer, and autoimmune disorders, while also preparing for future pharmaceutical innovations.
Opportunities for Skilled Talent
Recruitment for the new hub will begin immediately, targeting roles including engineers, chemists, analytical scientists, quality control and assurance professionals, and management positions. Lilly aims to leverage India’s highly skilled workforce to strengthen its global manufacturing capacity, ensuring quality and scalability of life-saving medicines worldwide.
Endorsements from Government and Industry Leaders
A. Revanth Reddy, Chief Minister of Telangana, highlighted Hyderabad’s emergence as a global healthcare innovation hub, praising Lilly’s expansion as a catalyst for regional industrial growth. Sridhar Babu, Telangana Minister for Industries & Commerce, emphasized the state’s strong infrastructure and business-friendly policies that attract global leaders like Lilly. Nivruti Rai, MD & CEO of Invest India, noted that Lilly’s commitment reflects India’s growing stature as a competitive global manufacturing and innovation destination.
Lilly’s Global Vision and Commitment
Patrik Jonsson, Executive VP and President of Lilly International, said the investment underscores Lilly’s mission to expand manufacturing capacity and ensure patients worldwide have access to essential medicines. By partnering with trusted contract manufacturers in India, Lilly is enhancing its ability to deliver high-quality medicines at scale while strengthening its global supply chain.
With existing facilities in Gurugram, Bengaluru, and Hyderabad, Eli Lilly’s strategic investments reaffirm its long-term commitment to India, combining local talent, innovation, and advanced manufacturing capabilities to support global healthcare needs.
